Amazon Care is shutting down at the end of 2022. Here's why In new editorial, FDA's Califf says biomedical field should prioritize chronic illness, addiction J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering Fitbit debuts afib detection in health-tracking smartwatch UPDATED: PACT Pharma to cull lead asset, divert 54 employees to new business development venture Approval, check. Now, can BioMarin make a commercial success of its hemophilia A gene therapy in Europe? Employers concerned about long-term mental health issues post-COVID: survey Brain Scientific's EEG headset caps off regulatory push with European approval Chasing GSK, Pfizer races to regulators after RSV vaccine paints positive impression in RENOIR phase 3 Intermountain Healthcare posts $2.7B profit thanks to SCL Health merger It's a spinoff: Novartis parts ways with Sandoz just as its generics biz shows signs of recovery Aktis makes waves with $84M extension as 3 big pharmas channel funds to radiopharmaceutical pipeline Featured Story | By Heather Landi Three years after it began piloting a primary care service for its employees that blended telehealth and in-person medical services, Amazon plans to shutter its Amazon Care service for employers. read more |
| |
|---|
|
Top Stories By Max Bayer FDA Commissioner Robert Califf says the biopharma industry and researchers should redouble its efforts to treat common chronic diseases and addiction. His comments came in a new editorial published in Science. read more By Angus Liu Johnson & Johnson and partner Legend Biotech already sell BCMA-targeted CAR-T therapy Carvykti. Now, the company has complemented that complex therapy with an off-the-shelf option. read more By Andrea Park Just a few months after Fitbit roped in FDA clearance for an algorithm that could be embedded into its eponymous health-tracking wearables to detect atrial fibrillation, the technology is ready to hit the ground running. read more By Max Bayer More than a month after axing 94 employees, PACT Pharma is culling its lead asset and diverting 54 of the laid-off employees to a new business development venture that's yet to be named. read more By Fraiser Kansteiner The European Commission gave Roctavian the all-clear, granting conditional marketing authorization to the med in adults with severe hemophilia A who don’t have factor VIII inhibitors. read more By Paige Minemyer Employers view long-term mental health as the key healthcare issue coming out of COVID-19, according to a new survey. read more By Andrea Park With a device that’s now been cleared in both the U.S. and Europe, preparing a patient for an EEG test is almost as easy as strapping on a bike helmet. read more By Nick Paul Taylor Pfizer has kept up the heat on GSK in the respiratory syncytial virus (RSV) vaccine race, joining its rival in posting positive phase 3 data and staying tucked in its slipstream with plans to seek approval in the fall. read more By Dave Muoio A $1.7 billion loss from investments would have dragged Intermountain well into the red were it not for more than $4.1 billion in affiliation contributions resulting from the merger deal. read more By Angus Liu Less than a year into a strategic review, Novartis has decided to spin off its generics unit Sandoz. The separation will allow both companies to pursue different capital allocation strategies, CEO Vas Narasimhan, M.D., said. read more By Gabrielle Masson Aktis Oncology has closed a series A extension round to the tune of $84 million, with big pharmas Merck Novartis and BMS joining to expand the biotech’s bandwidth for developing radiopharmaceutical cancer treatments. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
